ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX:SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here